Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Skapek, James Anderson, D. Hill, David Henry, S. Spunt, W. Meyer, S. Kao, F. Hoffer, H. Grier, D. Hawkins, R. Raney (2013)Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
Pediatric Blood & Cancer, 60
B. Kasper, A. Dimitrakopoulou-Strauss, L. Pilz, L. Strauss, C. Sachpekidis, P. Hohenberger (2013)Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
BioMed Research International, 2013
R. Woodgate, L. Degner, R. Yanofsky (2003)A different perspective to approaching cancer symptoms in children.
Journal of pain and symptom management, 26 3
Craft Aw, Pearson Ad (1989)Three decades of chemotherapy for childhood cancer: from cure 'at any cost' to cure 'at least cost'.
Cancer surveys, 8
N. Penel, A. Cesne, S. Bonvalot, A. Giraud, E. Bompas, M. Ríos, S. Salas, N. Isambert, P. Boudou-Rouquette, C. Honoré, A. Italiano, I. Ray-Coquard, S. Piperno-Neumann, F. Gouin, F. Bertucci, T. Ryckewaert, J. Kurtz, F. Ducimetière, J. Coindre, J. Blay (2017)Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group.
European journal of cancer, 83
K. Harati, A. Jaenisch, B. Behr, O. Goertz, A. Harati, T. Hirsch, I. Stricker, M. Lehnhardt, A. Daigeler (2017)Effect of surgical margins on prognosis in aggressive fibromatosis: A single-institutional analysis of 90 patients
Oncology Letters, 14
J. Jo, Y. Hong, Kyu-pyo Kim, Jae-Lyun Lee, Jeeyun Lee, Y. Park, S. Kim, J. Ryu, Jong-Seok Lee, Tae Kim (2014)A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis
Investigational New Drugs, 32
Michelle Ghert, Xiaomei Yao, Tom Corbett, A. Gupta, R. Kandel, S. Verma, J. Werier (2014)Treatment and follow-up strategies in desmoid tumours: a practice guideline.
Current oncology, 21 4
P. Peng, O. Hyder, M. Mavros, R. Turley, R. Groeschl, Amin Firoozmand, Michael Lidsky, J. Herman, M. Choti, N. Ahuja, R. Anders, D. Blazer, T. Gamblin, T. Pawlik (2012)Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients
Annals of Surgical Oncology, 19
J. Biermann (2000)Desmoid tumors
Current Treatment Options in Oncology, 1
Lawrence Faulkner, S. Hajdu, U. Kher, M. Quaglia, P. Exelby, G. Heller, N. Wollner (1995)Pediatric desmoid tumor: retrospective analysis of 63 cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 11
N. Penel, J. Coindre, S. Bonvalot, A. Italiano, A. Neuville, A. Cesne, P. Terrier, I. Ray-Coquard, D. Ranchère‐Vince, Y. Robin, N. Isambert, G. Ferron, F. Duffaud, F. Bertucci, M. Ríos, E. Stoeckle, C. Péchoux, C. Guillemet, J. Courreges, J. Blay (2016)Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France.
European journal of cancer, 58
S. Bonvalot, A. Desai, S. Coppola, C. Péchoux, P. Terrier, J. Dômont, A. Cesne (2012)The treatment of desmoid tumors: a stepwise clinical approach.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 10
Zerrin Greenacre (2016)The Importance of Selection Bias in Internet Surveys
Open Journal of Statistics, 06
M. Fiore, C. Colombo, S. Radaelli, D. Callegaro, E. Palassini, M. Barisella, C. Morosi, G. Baldi, S. Stacchiotti, P. Casali, A. Gronchi (2015)Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.
European journal of cancer, 51 18
R. Chugh, J. Wathen, Shreyaskumar Patel, R. Maki, P. Meyers, S. Schuetze, D. Priebat, Dafydd Thomas, J. Jacobson, B. Samuels, R. Benjamin, L. Baker (2010)Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Clinical Cancer Research, 16
S. Skapek, Bobbi Hawk, F. Hoffer, G. Dahl, L. Granowetter, M. Gebhardt, W. Ferguson, H. Grier (1998)Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 9
B. Kasper (2015)Systemic Treatment Approaches for Sporadic Desmoid-Type Fibromatosis: Scarce Evidence and Recommendations
Oncology Research and Treatment, 38
A. Crago, B. Denton, S. Salas, A. Dufresne, J. Mezhir, M. Hameed, M. Gonen, S. Singer, M. Brennan (2013)A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis
Annals of Surgery, 258
Evelyn Sharkey, Nancy Zoellner, S. Abadin, D. Gutmann, Kimberly Johnson (2015)Validity of participant-reported diagnoses in an online patient registry: a report from the NF1 Patient Registry Initiative.
Contemporary clinical trials, 40
S. Kummar, G. Coyne, K. Do, B. Turkbey, P. Meltzer, E. Polley, P. Choyke, R. Meehan, R. Vilimas, Yvonne Horneffer, L. Juwara, A. Lih, Alok Choudhary, S. Mitchell, L. Helman, J. Doroshow, A. Chen (2017)Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 14
Desmoid tumors are locally invasive sarcoma, affecting 5–6 individuals out of 1,000,000 per year. The desmoid tumors have high rates of recurrence after resection and can lead to significant deterioration of the quality of life of patients. There is a need for a better understanding of the desmoid tumors’ patient experience from first symptoms through diagnosis, disease monitoring, and clinical treatment options. With the National Organization of Rare Disorders, the Desmoid Tumor Research Foundation Natural History Study was designed to be collected through the registry. This article describes the protocol for the Desmoid Tumor Research Foundation Natural History Study and some initial findings. The Desmoid Tumor Research Foundation Natural History Study Advisory Committee developed a series of questionnaires and longitudinal surveys, in addition to those from the National Organization of Rare Disorders for all of the rare diseases. These 13 surveys are designed to uncover initial symptoms, diagnosis process, disease monitoring, quality of life, treatments, as well as socioeconomic information. Since launching the Desmoid Tumor Research Foundation Registry and Natural History Study (https://dtrf.iamrare.org), more than 300 desmoid tumor patients have consented to the Desmoid Tumor Research Foundation Natural History Study and completed the Participant Profile. The majority of the respondents are between the ages of 21 and 50 years (76%), female (81.2%), White (91.5%), and live in the United States (47.1%). The majority of tumors are in the lower or upper extremity, (22.9%) followed closely by abdominal desmoid tumors (21.5%). Most are willing to donate specimens (89.9%) and participate in trials (97.2%). Ongoing efforts are addressing the demographic differences between the respondents and non-respondents and any selection bias based on access to the registry and study. The Desmoid Tumor Research Foundation Natural History Study is built on the largest desmoid tumors registry and has recruited more desmoid tumors participants since launching in September 2017. It will serve to fill desmoid tumors knowledge gaps and assist other researchers in their recruitment efforts for additional studies.
Rare Tumors – SAGE
Published: Oct 14, 2019
Keywords: Desmoid tumor; aggressive fibromatosis; β-catenin; familial adenomatous polyposis; rare diseases; natural history study; patient registries; patient-reported outcomes; sarcoma
Access the full text.
Sign up today, get DeepDyve free for 14 days.